Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry
Daniele Armenia,Vincenzo Spagnuolo,Maria C Bellocchi,Laura Galli,Leonardo Duca,Greta Marchegiani,Tommaso Clemente,Luca Carioti,Riccardo Lolatto,Leonardo Calza,Benedetto M Celesia,Antonio Cascio,Daniela Francisci,Annalisa Saracino,Carlo Torti,Maurizio Zazzi,Antonella Castagna,Maria M Santoro,PRESTIGIO Study Group,Franco Maggiolo,Emanuele Focà,Filippo Lagi,Giovanni Cenderello,Antonio Di Biagio,Giulia Marchetti,Stefano Rusconi,Adriana Cervo,Roberta Gagliardini,Stefano Bonora,Anna Maria Cattelan,Maria Mercedes Santoro,Andrea Galli,Francesco Saladini,Elisabetta Carini,Sabrina Bagaglio,Sara Diotallevi,Marcello Tavio,Alessandra Mataloni Paggi,Francesca Vichi,Alessio Bellucci,Elisa Mirabelli,Flavia Balena,Laura Comi,Daniela Valenti,Claudia Suardi,Federica Malerba,Francesco Castelli,Davide Minisci,Francesca Pennati,Anna Celotti,Francesca Brognoli,Barbara Menzaghi,Maddalena Farinazzo,Bruno Cacopardo,Benedetto Maurizio Celesia,Michele Salvatore Paternò Raddusa,Carmen Giarratana,Paolo Fusco,Gabriele Bruno,Angelo Pan,Paola Brambilla,Chiara Fornabaio,Alessandro Bartoloni,Susanna Giachè,Paola Corsi,Seble Tekle Kiros,Filippo Ducci,Teresa Santantonio,Sergio Lo Caputo,Sergio Ferrara,Marianna Narducci,Emanuele Pontali,Marcello Feasi,Antonio Sarà,Matteo Bassetti,Sabrina Blanchi,Rebecka Papaioannu Borjesson,Spinello Antinori,Tiziana Formenti,Andrea Giacomelli,Lidia Gazzola,Federica De Flaviis,Massimo Puoti,Cristina Moioli,Federico D'Amico,Cristina Mussini,Roncaglia Enrica,Nardini Giulia,Barbara Beghetto,Elio Manzillo,Amedeo Lanzardo,Maria Mazzitelli,Marcello Trizzino,Elisa Fronti,Diletta Laccabue,Roberto Gulminetti,Andrea Zuccarini,Elisabetta Schiaroli,Giuseppe De Socio,Elisa Garlassi,Romina Corsini,Marisa Fusto,Loredana Sarmati,Vincenzo Malagnino,Silvia Lamonica,Simona Di Giambenedetto,Tiziana Mulas,Rachele Pincino,Mario Tumbarello,Massimiliano Fabbiani,Francesca Panza,Ilaria Rancan,Giovanni Di Perri,Micol Ferrara,Silvia Fantino,Marina Malena,Marta Fiscon
DOI: https://doi.org/10.1093/jac/dkae236
2024-09-03
Abstract:Background: To clarify whether next-generation sequencing (NGS) can be useful for resistance assessment in virologically suppressed highly treatment-experienced (HTE) individuals with MDR HIV. Methods: Ninety-one participants from the PRESTIGIO Registry were included. NGS was performed on HIV-DNA at 1%, 5% and 20% cut-offs; major drug resistance mutations (DRMs) were evaluated and compared with those detected in historical plasma genotypic resistance testing (h-GRT). APOBEC editing was also characterized. Results: Participants had a complex and long treatment history [median 23 (IQR 21-25) years of ART exposure) and had been virologically suppressed since a median of 3 (IQR 2-5) years. Among all major DRMs detected by HIV-DNA NGS and/or h-GRT, 30% were exclusively found through NGS. The highest detection rate of historical major DRMs was reached with NGS set at 1%, but unusual substitutions and extensive APOBEC hypermutations suggest technical issues and poor clinical relevance in the 1%-5% interval. At NGS set at 5%, 67.2% of historical major DRMs were detected. The number of major DRMs detected exclusively by DNA-NGS as minority variants (frequency 5%-20%) was significantly higher in individuals who later experienced virological rebound compared with those who maintained virological control [median 2 (IQR 1-3) versus 1 (0-2), P = 0.030] and positively correlated with viraemia levels at rebound (rho = 0.474, P = 0.030). Conclusions: In non-viraemic people with an MDR virus, HIV-1 DNA NGS set at 5% is an acceptable technical cut-off that might help to reveal mutations with a potential clinical relevance. Moreover, the number of minority resistance mutations additionally detected by NGS might be associated with loss of virological control.